RxDoctor Payments Data

Christi Pagett, MD

Family Medicine · Evansville, INNPI 1477815819

Payments from drug & device makers

$5,871in general payments, 2019–2025

Across 384 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$502
  • Novo Nordisk$432
  • Amgen$365
  • Pfizer$341
  • GSK$326
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$5,56495%
  • Education$3075%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,871 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$153,193
Medicare patients
264
Services billed
2,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$44,906
MounjaroTirzepatide29$38,314
EliquisApixaban32$35,946
OzempicSemaglutide14$16,233
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,289
Repatha SureclickEvolocumab13$14,272
FarxigaDapagliflozin Propanediol16$11,077
Praluent PenAlirocumab11$10,745
Advair HfaFluticasone Propion/Salmeterol17$4,913
SynthroidLevothyroxine Sodium40$3,153
Atorvastatin Calcium433$3,007
Metoprolol Succinate237$2,867
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,702
Memantine Hcl ErMemantine Hcl20$2,125
Losartan Potassium249$2,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$204$44,90633 claims
Lilly USA, LLCMounjaro$188$38,31429 claims
PfizerEliquis, Paxlovid$341$37,37545 claims
Novo NordiskOzempic$432$16,23314 claims
GSKTrelegy Ellipta$326$14,28917 claims
AstraZenecaFarxiga$164$11,07716 claims
AbbVieSynthroid$1,282$3,15340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →